Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Lymphotropic Virotherapy Induces DC and High Endothelial Venule Inflammation, Promoting the Antitumor Efficacy of Intratumor Virus Administration.

Cancer immunology research·2025

Same author

EGFR phosphorylation of DCBLD2 recruits TRAF6 and stimulates AKT-promoted tumorigenesis.

The Journal of clinical investigation·2025

Same author

Lymphotropic Virotherapy Engages DC and High Endothelial Venule Inflammation to Mediate Cancer <i>In Situ</i> Vaccination.

medRxiv : the preprint server for health sciences·2025

Same author

Development of a high-throughput screening platform to identify new therapeutic agents for Medulloblastoma Group 3.

SLAS discovery : advancing life sciences R & D·2024

Same author

Repurposing Clemastine to Target Glioblastoma Cell Stemness.

Cancers·2023

Same author

Intratumor childhood vaccine-specific CD4<sup>+</sup> T-cell recall coordinates antitumor CD8<sup>+</sup> T cells and eosinophils.

Journal for immunotherapy of cancer·2023

Search research articles

Related Experiment Video

Updated: May 24, 2026

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

Toxin-based targeted therapy for malignant brain tumors.

Vidyalakshmi Chandramohan¹, John H Sampson, Ira Pastan

¹Department of Pathology, Duke University Medical Center, Durham, NC 27710, USA.

Clinical & Developmental Immunology

|March 9, 2012

Summary

Novel recombinant fusion proteins targeting brain tumors show promise. These therapies, personalized to tumor characteristics, are demonstrating encouraging results in clinical trials, stabilizing disease and prolonging survival.

More Related Videos

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

Nanoparticle Delivery of an Oligonucleotide Payload in a Glioblastoma Multiforme Animal Model

Nanoparticle Delivery of an Oligonucleotide Payload in a Glioblastoma Multiforme Animal Model

Published on: September 27, 2024

Related Experiment Videos

Last Updated: May 24, 2026

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

Nanoparticle Delivery of an Oligonucleotide Payload in a Glioblastoma Multiforme Animal Model

Nanoparticle Delivery of an Oligonucleotide Payload in a Glioblastoma Multiforme Animal Model

Published on: September 27, 2024

Area of Science:

Oncology
Neuroscience
Biotechnology

Background:

Malignant brain tumors, particularly high-grade astrocytic tumors, have a poor prognosis despite conventional treatments like surgery, radiotherapy, and chemotherapy.
The complex and diffuse nature of these tumors necessitates innovative therapeutic strategies.
Genomic and proteomic research enables personalized treatment approaches based on tumor-specific characteristics.

Purpose of the Study:

To review the preclinical and clinical findings of recombinant fusion protein conjugates for treating central nervous system neoplasia.
To evaluate the potential of tumor-antigen-directed cytotoxic proteins as a safe and effective therapy for brain tumors.

Main Methods:

Investigation of novel drug candidates: recombinant fusion protein conjugates armed with cytotoxic agents.
Targeting of tumor-specific antigens for precise drug delivery.
Summary of major findings from preclinical studies and ongoing clinical trials.

Main Results:

Encouraging results from ongoing clinical trials have been observed in at least 109 cases.
Observed outcomes include disease stabilization and prolongation of patient survival.
Preclinical and clinical data support the investigation of antiglioma cytotoxins.

Conclusions:

Recombinant fusion protein conjugates represent a promising novel therapeutic class for malignant brain tumors.
Personalized medicine approaches, guided by tumor genomics and proteomics, are advancing brain tumor treatment.
Clinical trials indicate the potential safety and efficacy of these targeted cytotoxic proteins in improving patient outcomes.